PropThink: VEN-307 is Ideal for a Small Company to Launch, says Ventrus CEO
[ACN Newswire] – Ventrus Biosciences (NASDAQ:VTUS) believes it has hit the trifecta of anal fissure endpoints with its lead candidate VEN-307. In a 465 patient Phase III trial, CEO Russel Ellison says the company … more
View todays social media effects on VTUS
View the latest stocks trending across Twitter. Click to view dashboard